Nasdaq

Aura Biosciences to Present Phase 1 Data on Bel-sar and Host Virtual Urologic Oncology Investor Event at 40th Annual EAU Congress

Aura Biosciences will present Phase 1 data on bel-sar for bladder cancer at the EAU Congress and host an investor event. Aura Biosciences, Inc. announced its participation in the 40th Annual European ...
Seeking Alpha

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences (AURA), Inc. (NASDAQ: AURA), today announced positive data from a completed Phase 1 window of opportunity trial of bel-sar (AU-011) in ...
Seeking Alpha

Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value

Aura Biosciences, Inc. (AURA) has been able to advance its pipeline with great clinical success in the last several months. That's because it has been able to report positive results from two studies ...